<DOC>
	<DOCNO>NCT00038818</DOCNO>
	<brief_summary>Primary Objectives : To evaluate response rate acute chronic Graft-versus-host disease ( GVHD ) follow CD8 deplete DLI ( Depleted Donor Lymphocyte Infusions ) patient Chronic myelomonocytic leukemia ( CMML ) , chronic lymphoid leukemia ( CLL ) , Non-Hodgkin 's lymphoma ( NLM ) , Multiple Myeloma ( MM ) Hodgkin 's Lymphoma ( HD ) . Secondary Objectives : - To evaluate safety treatment related mortality CD8 deplete DLI . - To evaluate time onset GVHD follow DLI response GVHD treatment . - To evaluate incidence time pancytopenia follow DLI . - To evaluate disease-free survival , overall survival relapse rate three cohort patient ; early relapse CML , late relapse CML lymphoproliferative disorder ( HD , CLL , NHL MM ) . - To evaluate need efficacy second subsequent CD8 deplete donor lymphocyte infusion . - To evaluate number apheresis procedure need collect appropriate dos CD4+ cell .</brief_summary>
	<brief_title>CD8 DLI Patients With Relapse Residual Disease Following Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patients age previously undergone allogeneic hematopoietic transplantation evidence donor cell engraftment ( &gt; 20 % donor cell within three month study entry ) Expected survival &gt; 4 week CML patient molecular , cytogenetic hematologic relapse follow allogeneic transplantation 1 . Molecular relapse patient eligible bcr/abl detectable time day 180 postallogeneic transplantation negative bcr/abl PCR test document posttransplantation bcr/abl test positive consecutive PCR determination least 4 week apart . 2 . Cytogenetic relapsepatients eligible standard cytogenetics demonstrate &gt; 10 % ( 9,22 ) positive cell great 60 day myeloablative transplantation 10 % ( 9,22 ) positive cell great 100 day nonmyeloablative transplantation . CML patient accelerate phase blast crisis follow allogeneic transplantation Patients CLL , NHL , MM , HD evidence disease relapse persistent disease 60 day postallo BMT and/or : 1 . MM patient rise Mprotein detectable 180 day posttransplant 2 . NHL patient molecular evidence disease ( bcl2 , ( 4,11 ) , etc . ) 180 day post transplant 3 . CLL , NHL HD patient clear cut evidence tumor growth time posttransplant eligible Patients undergo HLA identical 5/6 antigen match transplant relate unrelated donor Patient 's original donor must available lymphocyte donation There must evidence active acute graftversushost disease patient immunosuppressive agent , least , two week prior DLI . Patients stable dose methylprednisolone ( &lt; 16 mg/d ) without evidence active GVHD also eligible . Patients must Zubrod PS &lt; 2 ( see appendix 7 ) , Cr &lt; 2.5 , bilirubin &lt; 3 , transaminase ( SGPT , SGOT ) &lt; 4x normal Patient must able sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>CML</keyword>
	<keyword>MM</keyword>
	<keyword>NHL</keyword>
	<keyword>HD</keyword>
	<keyword>CLL</keyword>
	<keyword>CD8 Depleted</keyword>
	<keyword>Donor Lymphocyte</keyword>
</DOC>